Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study

Basit Öğe Kaydı
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorGumus, Mahmut
dc.contributor.authorOzkan, Metin
dc.contributor.authorDane, Faysal
dc.contributor.authorElkiran, Emin T.
dc.contributor.authorCicin, Irfan
dc.contributor.authorSevinc, Alper
dc.date.accessioned2024-02-23T14:27:01Z
dc.date.available2024-02-23T14:27:01Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractObjective Cytokines have been the mainstay of treatment in metastatic renal cell cancer (mRCC) for decades before the introduction of tyrosine kinase inhibitors (TKIs), which dramatically changed the therapeutic landscape in these patients. This observational study was designed to evaluate use of TKIs in the treatment of cytokine-intolerant mRCC patients. Methods A total of 151 cytokine-intolerant mRCC patients who were treated with TKIs (sunitinib, pazopanib and sorafenib) were enrolled in this prospective, non-interventional, multi-center observational study at 16 oncology centers across Turkey. Mean (SD) age was 61.3 (11.1) years and 74.8% were males. Data on duration of TKI treatment was the primary outcome measure. Additionally, overall response rate (ORR), progression free survival (PFS), overall survival (OS) and safety data were recorded. Results Median duration of treatment was 8.2 months at a median follow up of 17.9 months. ORR and disease control rate were 12.5% and 70.8%, respectively. Median PFS and OS were 7.5 months (95%CI: 6.4-10.4) and 27.3 months (95%CI: 17.6-27.3) with no significant difference among three TKI agents in terms of treatment duration, ORR, PFS and OS. The most common adverse events excluding progression-which was the protocol requirement were diarrhea (13.6%), asthenia (13.6%) and hand-foot syndrome (12.6%). Dose modifications were required in 30.5% of the patients and 15% discontinued TKIs because of toxicity. Conclusions Our findings confirm the efficacy and safety profile of TKIs in the first-line treatment of mRCC patients intolerant to cytokine treatment. There was no significant difference among three TKI agents in terms of treatment duration, ORR, PFS and OS.en_US
dc.description.sponsorshipBayer Turken_US
dc.description.sponsorshipThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by Bayer Turk (ClinicalTrials.gov Identifier: NCT01585974).en_US
dc.identifier.doi10.1177/1078155220963535
dc.identifier.endpage1630en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue7en_US
dc.identifier.pmid33050804en_US
dc.identifier.scopus2-s2.0-85092561865en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1623en_US
dc.identifier.urihttps://doi.org/10.1177/1078155220963535
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14422
dc.identifier.volume27en_US
dc.identifier.wosWOS:000578499200001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMetastatic Renal Cell Carcinomaen_US
dc.subjectTyrosine Kinase Inhibitorsen_US
dc.subjectCytokine Intoleranceen_US
dc.subjectProgression-Free Survivalen_US
dc.subjectOverall Survivalen_US
dc.subjectSafetyen_US
dc.titleTyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu